Akella Prasanth Saraswati

Akella Prasanth Saraswati

Auto-generated profile, based on publicly available information

Akella Prasanth Saraswati

Basic Medical Sciences College of Veterinary Medicine Purdue University West Lafayette IN 47907 USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2017 in MedChemComm
Verified
Journal Article
Closed access
PDF file
ZSZaki S. Seddigi
Zaki S. Seddigi
MMMohammed Shaheer Malik
Mohammed Shaheer Malik
ASA Prasanth Saraswati
A Prasanth Saraswati
SASaleh A Ahmed
Saleh A Ahmed
ABAhmed O. Babalghith
Ahmed O. Babalghith
AKAhmed Kamal
Ahmed Kamal
The dynamic and crucial role of tubulin in different cellular functions rendered it a promising target in anticancer drug development. Combretastatin A-4 (CA-4), an inhibitor of tubulin polymerization isolated from natural sources, is a lead molecule with significant cytotoxicity against tumour cells. Owing to its non polar nature it exhibits low solubility in natural biological fluids, thereby prompting the development of new CA-4 based derivatives. The modification of this lead molecule was mostly carried out by keeping the crucial cis-orientation of the double bond intact, along with a trimethoxyphenyl aromatic ring, by employing different approaches. The issue of solubility was also addressed by the development of water soluble prodrugs of CA-4. The present review highlights the investigations into the parallel development of both new CA-4 based derivatives and prodrugs in the past few years.

12 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GCGiuseppe Campiani
Giuseppe Campiani
CCCaterina Cavella
Caterina Cavella
JOJeremy D. Osko
Jeremy D. Osko
Margherita BrindisiMargherita Brindisi
Margherita Brindisi
NRNicola Relitti
Nicola Relitti
APAntje Prasse
Antje Prasse

1 February 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NRNicola Relitti
Nicola Relitti
ASA. Prasanth Saraswati
A. Prasanth Saraswati
GCGiulia Chemi
Giulia Chemi
MBMargherita Brindisi
Margherita Brindisi
Simone BrogiSimone Brogi
Simone Brogi
GCGiuseppe Campiani
Giuseppe Campiani

5 August 2022 in Advanced Biology
Verified
Journal Article
Open access
ASAlyssa A. Smith
Alyssa A. Smith
KMKendall B. E. Moore
Kendall B. E. Moore
PAPatrick M. Ambs
Patrick M. Ambs
ASAkella Prasanth Saraswati
Akella Prasanth Saraswati
JFJessica Sonia Fortin
Jessica Sonia Fortin
In humans with type 2 diabetes, at least 70% of patients exhibit islet amyloid plaques formed by misfolding islet amyloid polypeptides (IAPP). The oligomeric conformation and accumulation of the IAPP plaques lead to a panoply of cytotoxic effects on the islet β‐cells. Currently, no marketed therapies for the prevention or elimination of these amyloid deposits exist, and therefore significant efforts are required to address this gap. To date, most of the experimental treatments are limited to only in vitro stages of testing. In general, the proposed therapeutics use various targeting strategies, such as binding to the N‐terminal region of islet amyloid polypeptide on residues 1–19 or the hydrophobic region of IAPP. Other strategies include targeting the peptide self‐assembly through π‐stacking. These methods are realized by using several different families of compounds, four of which are highlighted in this review: naturally occurring products, small molecules, organometallic compounds, and nanoparticles. Each of these categories holds immense potential to optimize and develop inhibitor(s) of pancreatic amyloidosis in the near future.

26 April 2022 in ChemMedChem
Verified
Journal Article
Open access
NRNicola Relitti
Nicola Relitti
ASA. Prasanth Saraswati
A. Prasanth Saraswati
Gabriele CarulloGabriele Carullo
Gabriele Carullo
APAlessandro Papa
Alessandro Papa
AMAlessandra Monti
Alessandra Monti
Doti NunziannaDoti Nunzianna
Doti Nunzianna
Pin1 catalyzes the cis‐trans isomerization of pThr‐Pro or pSer‐Pro amide bonds of various proteins involved in several physio/pathological processes. In this framework, recent research activity is directed toward the identification of new selective Pin1 inhibitors. Here, we developed a set of peptide‐based Pin1 inhibitors. Direct‐binding experiments allowed the identification of the peptide‐based inhibitor 5 k (methylacetyl‐l‐alanyl‐l‐histidyl‐l‐prolyl‐l‐phenylalaninate) as a potent ligand of Pin1. Notably, 5 k binds Pin1 with higher affinity than Pin4. The comparative analysis of molecular models of Pin1 and Pin4 with the selected compound gave a rational explanation of the biochemical activity and pinpointed the chemical elements that, if opportunely modified, may further improve inhibitory potency, pharmacological properties, and selectivity of future peptide‐based parvulin inhibitors. Since 5 k showed limited cell penetration and no antiproliferative activity, it was conjugated to a polyarginine stretch (R8), known to promote cell penetration of peptides, to obtain the R8–5 k derivative, which displayed antiproliferative effects on cancer cell lines over non‐tumor cells. The effect of R8 on cell proliferation was also investigated. This work warrants caution about applying the R8 strategy in the development of cell‐penetrating antiproliferative peptides, as it is not inert.